Protein Phosphatase 2A (PP2A or EC 3.1.3.16)-Pipeline Review, H2 2016

Protein Phosphatase 2A (PP2A or EC 3.1.3.16)-Pipeline Review, H2 2016


  • Products Id :- GMDHC0455TDB
  • |
  • Pages: 45
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Protein Phosphatase 2A (PP2A or EC 3.1.3.16)-Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Protein Phosphatase 2A (PP2A or EC 3.1.3.16)-Pipeline Review, H2 2016', provides in depth analysis on Protein Phosphatase 2A (PP2A or EC 3.1.3.16) targeted pipeline therapeutics.

The report provides comprehensive information on the Protein Phosphatase 2A (PP2A or EC 3.1.3.16), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Protein Phosphatase 2A (PP2A or EC 3.1.3.16) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

*Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Protein Phosphatase 2A (PP2A or EC 3.1.3.16)

The report reviews Protein Phosphatase 2A (PP2A or EC 3.1.3.16) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Protein Phosphatase 2A (PP2A or EC 3.1.3.16) targeted therapeutics and enlists all their major and minor projects

The report assesses Protein Phosphatase 2A (PP2A or EC 3.1.3.16) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Protein Phosphatase 2A (PP2A or EC 3.1.3.16) targeted therapeutics

Reasons to Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Protein Phosphatase 2A (PP2A or EC 3.1.3.16)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Protein Phosphatase 2A (PP2A or EC 3.1.3.16) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Protein Phosphatase 2A (PP2A or EC 3.1.3.16) Overview 6

Therapeutics Development 7

Protein Phosphatase 2A (PP2A or EC 3.1.3.16)-Products under Development by Stage of Development 7

Protein Phosphatase 2A (PP2A or EC 3.1.3.16)-Products under Development by Therapy Area 8

Protein Phosphatase 2A (PP2A or EC 3.1.3.16)-Products under Development by Indication 9

Protein Phosphatase 2A (PP2A or EC 3.1.3.16)-Pipeline Products Glance 11

Late Stage Products 11

Early Stage Products 12

Protein Phosphatase 2A (PP2A or EC 3.1.3.16)-Products under Development by Companies 13

Protein Phosphatase 2A (PP2A or EC 3.1.3.16)-Therapeutics Assessment 15

Assessment by Monotherapy/Combination Products 15

Assessment by Mechanism of Action 16

Assessment by Route of Administration 18

Assessment by Molecule Type 20

Protein Phosphatase 2A (PP2A or EC 3.1.3.16)-Companies Involved in Therapeutics Development 21

Ampio Pharmaceuticals, Inc. 21

Bristol-Myers Squibb Company 22

Cyano Biotech GmbH 23

Lixte Biotechnology Holdings, Inc. 24

Signum Biosciences, Inc. 25

Protein Phosphatase 2A (PP2A or EC 3.1.3.16)-Drug Profiles 26

Drugs to Activate PP2A for Oncology-Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

DT-1154-Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

LB-100-Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

NCE-001-Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

Small Molecules to Activate PP2A for Parkinson Disease and Alzheimer's Disease-Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

Small Molecules to Inhibit PP1 and PP2A for Oncology-Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

VEL-015-Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

Protein Phosphatase 2A (PP2A or EC 3.1.3.16)-Dormant Projects 36

Protein Phosphatase 2A (PP2A or EC 3.1.3.16)-Featured News & Press Releases 37

Feb 03, 2016: Lixte Biotechnology Holdings Lead Compound LB-100 Reported to Rapidly Improve Symptoms in a Rodent Model of Depression 37

Nov 06, 2015: Lixte Biotechnology Holdings Announces That Its Novel Protein Phosphatase 2A Inhibitor Is Associated With Stabilization Of Several Types Of Cancer Without Dose-Limiting Toxicity 37

Sep 17, 2015: Lixte Biotechnology Holdings Engages BioPharmaWorks To Enhance Development Of Its Pipeline Of Novel Compounds 38

Feb 25, 2015: Lixte Biotechnology's Lead Compound Reported To Be Active Against Hematologic Cancers In Pre-Clinical Studies 38

Jan 23, 2015: Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 39

Nov 06, 2014: Lixte's LB-100 Selected as One of Informa and Kantar Health's 2014 Top 10 Most Interesting Oncology Projects to Watch 39

Jun 18, 2014: Lixte's Lead Compound LB-100 Reported To Enhance Chemotherapy Effectiveness In Animal Models Of Liver Cancer 40

Apr 25, 2013: Lixte Biotechnology Initiates Phase I Trial Of Its Lead Anti-Cancer Compound LB-100 41

Jul 31, 2012: Lixte Biotechnology Announces Increased Funding And FDA Allowance To Conduct Phase I Trial Of LB-100 41

Jul 16, 2012: Ampio Pharma Advances NCE001 Cancer Drug Into Preclinical Development 41

May 01, 2012: Lixte Submits Investigational New Drug Application To FDA For Approval Of Clinical Trial Of LB-100 42

Sep 22, 2011: Lixte Biotechnology Receives US Patent For LB-100 42

Oct 05, 2010: Lixte Collaborates With NCI For Clinical Evaluation Of LB-100 43

Appendix 44

Methodology 44

Coverage 44

Secondary Research 44

Primary Research 44

Expert Panel Validation 44

Contact Us 44

Disclaimer 45

List of Figures

Number of Products under Development for, H2 2016 7

Number of Products under Development by Therapy Area, H2 2016 8

Number of Products under Development by Top 10 Indication, H2 2016 9

Comparative Analysis by Early Stage Products, H2 2016 12

Assessment by Monotherapy/Combination Products, H2 2016 15

Number of Products by Mechanism of Actions, H2 2016 16

Number of Products by Stage and Mechanism of Actions, H2 2016 16

Number of Products by Routes of Administration, H2 2016 18

Number of Products by Stage and Routes of Administration, H2 2016 18

Number of Products by Stage and Molecule Type, H2 2016 20

List of Tables

Number of Products under Development for, H2 2016 7

Number of Products under Development by Therapy Area, H2 2016 8

Number of Products under Development by Indication, H2 2016 10

Comparative Analysis by Late Stage Development, H2 2016 11

Comparative Analysis by Early Stage Products, H2 2016 12

Number of Products under Development by Companies, H2 2016 13

Products under Development by Companies, H2 2016 14

Assessment by Monotherapy/Combination Products, H2 2016 15

Number of Products by Stage and Mechanism of Action, H2 2016 17

Number of Products by Stage and Route of Administration, H2 2016 19

Number of Products by Stage and Molecule Type, H2 2016 20

Pipeline by Ampio Pharmaceuticals, Inc., H2 2016 21

Pipeline by Bristol-Myers Squibb Company, H2 2016 22

Pipeline by Cyano Biotech GmbH, H2 2016 23

Pipeline by Lixte Biotechnology Holdings, Inc., H2 2016 24

Pipeline by Signum Biosciences, Inc., H2 2016 25

Dormant Projects, H2 2016 36

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Ampio Pharmaceuticals, Inc.

Bristol-Myers Squibb Company

Cyano Biotech GmbH

Lixte Biotechnology Holdings, Inc.

Signum Biosciences, Inc.

Protein Phosphatase 2A (PP2A or EC 3.1.3.16) Therapeutic Products under Development, Key Players in Protein Phosphatase 2A (PP2A or EC 3.1.3.16) Therapeutics, Protein Phosphatase 2A (PP2A or EC 3.1.3.16) Pipeline Overview, Protein Phosphatase 2A (PP2A or EC 3.1.3.16) Pipeline, Protein Phosphatase 2A (PP2A or EC 3.1.3.16) Pipeline Assessment

select a license

Single User License
USD 3500 INR 224280
Site License
USD 7000 INR 448560
Corporate User License
USD 10500 INR 672840

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com